Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

著者: Angelo Di Leo, Stephen Johnston, Keun Seok Lee, Eva Ciruelos, Per Eystein Lønning, Wolfgang Janni, Ruth O’Regan, Marie‐Ange Mouret‐Reynier, Dimitar Kalev, Daniel Egle, Tibor Csőszi, Roberto Bordonaro, Thomas Decker, Vivianne C. G. Tjan‐Heijnen, Sibel Blau, Alessio Schirone, Denis Weber, Mona El-Hashimy, Bharani Dharan, Dalila Sellami, Thomas Bachelot - The Lancet 2017 被引用: 381